Literature DB >> 21445998

Neuropsychiatric symptoms and quality of life in patients with very mild and mild Alzheimer's disease.

Kristiina Karttunen1, Pertti Karppi, Asta Hiltunen, Matti Vanhanen, Tarja Välimäki, Janne Martikainen, Hannu Valtonen, Juhani Sivenius, Hilkka Soininen, Sirpa Hartikainen, Jaana Suhonen, Tuula Pirttilä.   

Abstract

BACKGROUND: Neuropsychiatric symptoms (NPS) are common manifestations of Alzheimer' s disease (AD).
OBJECTIVE: To examine the prevalence and significance of NPS in very mild and mild AD patients with emphasis on their influence on the well-being of the patients and their caregivers.
METHODS: The participants were 240 patient-caregiver dyads who participated in a prospective, controlled rehabilitation study (ALSOVA). Three Quality of Life (QoL) instruments were used; generic 15D, disease-specific QoL-AD and Visual Analog Scale (VAS). The disease-specific QoL-AD was both self-rated and caregiver rated. Other scales used were Mini-Mental State Examination (MMSE), Clinical Dementia Rating (CDR), ADCS-ADL, Neuropsychiatric Inventory (NPI) and Beck Depression Inventory (BDI).
RESULTS: NPS were present in 76.5% of patients with very mild AD (CDR 0.5) and in 84.9% of patients with mild to moderate AD (CDR 1). The most frequent symptoms were apathy, depression, irritability, and agitation. The strongest predictor of self-reported QoL-AD scores was depressive symptoms whereas functional decline and presence of NPS predicted poor caregiver ratings of patients' QoL. However, caregiver depression also influenced significantly their ratings.
CONCLUSION: NPS are common even in the early stages of AD. NPS were significantly associated with caregiver assessment of the patient's QoL but not with patients' self-assessed QoL. Depression decreases QoL, but may remain unrecognized in AD patients, emphasizing the need for careful and structured assessment of NPS before deciding on the appropriate treatment.
Copyright © 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 21445998     DOI: 10.1002/gps.2550

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  50 in total

1.  Latent Classes of Neuropsychiatric Symptoms in NACC Controls and Conversion to Mild Cognitive Impairment or Dementia.

Authors:  Jeannie-Marie S Leoutsakos; Sarah N Forrester; Constantine G Lyketsos; Gwenn S Smith
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 2.  Depression in cognitive impairment.

Authors:  Laurel D Pellegrino; Matthew E Peters; Constantine G Lyketsos; Christopher M Marano
Journal:  Curr Psychiatry Rep       Date:  2013-09       Impact factor: 5.285

3.  Prevalence of Depression, Anxiety and PTSD in People with Dementia: a Systematic Review and Meta-Analysis.

Authors:  J K Kuring; J L Mathias; L Ward
Journal:  Neuropsychol Rev       Date:  2018-12-07       Impact factor: 7.444

4.  Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment.

Authors:  Zahinoor Ismail; Eric E Smith; Yonas Geda; David Sultzer; Henry Brodaty; Gwenn Smith; Luis Agüera-Ortiz; Rob Sweet; David Miller; Constantine G Lyketsos
Journal:  Alzheimers Dement       Date:  2015-06-18       Impact factor: 21.566

5.  Nonpharmacologic management of behavioral symptoms in dementia.

Authors:  Laura N Gitlin; Helen C Kales; Constantine G Lyketsos
Journal:  JAMA       Date:  2012-11-21       Impact factor: 56.272

6.  Reduced quality-of-life ratings in mild cognitive impairment: analyses of subject and informant responses.

Authors:  Edmond Teng; Kanida Tassniyom; Po H Lu
Journal:  Am J Geriatr Psychiatry       Date:  2012-12       Impact factor: 4.105

Review 7.  Assessing neuropsychiatric symptoms in people with dementia: a systematic review of measures.

Authors:  Laura N Gitlin; Katherine A Marx; Ian H Stanley; Bryan R Hansen; Kimberly S Van Haitsma
Journal:  Int Psychogeriatr       Date:  2014-08-06       Impact factor: 3.878

8.  Management of patients with Alzheimer's disease: pharmacological treatment and quality of life.

Authors:  Enrico Mossello; Elena Ballini
Journal:  Ther Adv Chronic Dis       Date:  2012-07       Impact factor: 5.091

9.  Subscale validation of the neuropsychiatric inventory questionnaire: comparison of Alzheimer's disease neuroimaging initiative and national Alzheimer's coordinating center cohorts.

Authors:  Paula T Trzepacz; Andrew Saykin; Peng Yu; Phani Bhamditipati; Jia Sun; Ellen B Dennehy; Brian Willis; Jeffrey L Cummings
Journal:  Am J Geriatr Psychiatry       Date:  2013-04-18       Impact factor: 4.105

10.  Biomarkers of vascular risk, systemic inflammation, and microvascular pathology and neuropsychiatric symptoms in Alzheimer's disease.

Authors:  James R Hall; April R Wiechmann; Leigh A Johnson; Melissa Edwards; Robert C Barber; A Scott Winter; Meharvan Singh; Sid E O'Bryant
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.